VEGFC and lung carcinoma: Tammela et al. studying VEGF-C and VEGF-D delivery by adenovirus in rats that underwent VLNT, demonstrated through subcutaneous injection of human lung carcinoma cells, that cancer cells were trapped in 80% of VEGF-C-treated lymph nodes (8/10) versus only 17% in the control group (1/6) [21].